Simplex Trading
CRSP icon

Simplex Trading’s CRISPR Therapeutics CRSP Stock Holding History

Simplex Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.02M Sell
63,400
-117,800
-65% -$6.21M ﹤0.01% 1502
2025
Q4 		$9.5M Sell
181,200
-24,900
-12% -$1.49M 0.01% 877
2025
Q3 		$13.4M Buy
206,100
+8,300
+4% +$477K 0.01% 804
2025
Q2 		$9.62M Sell
197,800
-17,800
-8% -$689K 0.01% 910
2025
Q1 		$7.34M Buy
215,600
+69,600
+48% +$2.95M ﹤0.01% 1066
2024
Q4 		$5.75M Sell
146,000
-1,300
-0.9% -$61.4K ﹤0.01% 1382
2024
Q3 		$6.92M Sell
147,300
-43,600
-23% -$2.21M ﹤0.01% 1265
2024
Q2 		$10.3M Sell
190,900
-113,200
-37% -$6.55M 0.01% 1001
2024
Q1 		$20.7M Buy
304,100
+54,100
+22% +$3.87M 0.01% 675
2023
Q4 		$15.7M Buy
250,000
+166,800
+200% +$9.22M 0.01% 841
2023
Q3 		$3.78M Sell
83,200
-68,400
-45% -$3.53M ﹤0.01% 1532
2023
Q2 		$8.51M Buy
151,600
+62,400
+70% +$3.54M 0.01% 988
2023
Q1 		$4.03M Sell
89,200
-88,900
-50% -$4.32M ﹤0.01% 1444
2022
Q4 		$7.24M Buy
178,100
+67,800
+61% +$3.6M 0.01% 1011
2022
Q3 		$7.21M Sell
110,300
-16,300
-13% -$1.18M 0.01% 961
2022
Q2 		$7.69M Buy
126,600
+54,100
+75% +$3.18M 0.01% 918
2022
Q1 		$4.55M Sell
72,500
-97,700
-57% -$6.13M ﹤0.01% 1327
2021
Q4 		$12.9M Buy
170,200
+83,400
+96% +$7.29M 0.01% 680
2021
Q3 		$13.6M Buy
86,800
+2,100
+2% +$264K 0.01% 589
2021
Q2 		$13.7M Buy
84,700
+83,844
+9,795% +$10.2M 0.01% 581
2021
Q1 		$10.4M Sell
856
-79
-8% -$11.9K 0.02% 453
2020
Q4 		$14.3M Buy
935
+591
+172% +$69.9K 0.02% 447
2020
Q3 		$2.88M Sell
344
-159
-32% -$14.1K ﹤0.01% 1241
2020
Q2 		$3.7M Buy
503
+185
+58% +$10.8K 0.01% 1048
2020
Q1 		$1.35M Buy
318
+10
+3% +$516 ﹤0.01% 1617
2019
Q4 		$1.88M Buy
308
+21
+7% +$1.15K ﹤0.01% 1537
2019
Q3 		$1.18M Sell
287
-186
-39% -$8.89K ﹤0.01% 1781
2019
Q2 		$2.23M Buy
473
+48
+11% +$1.92K 0.01% 1226
2019
Q1 		$1.52M Buy
425
+129
+44% +$4.46K ﹤0.01% 1615
2018
Q4 		$845K Buy
296
+218
+279% +$7.58K ﹤0.01% 1768
2018
Q3 		$345K Buy
78
+44
+129% +$2.3K ﹤0.01% 3014
2018
Q2 		$199K Buy
34
+12
+55% +$684 ﹤0.01% 3494
2018
Q1 		$44K Buy
22
+11
+100% +$454 ﹤0.01% 2561
2017
Q4 		$11K Buy
+11
New +$209 ﹤0.01% 3793
2017
Q3 		– Sell
-20
Closed -$1K – 5983
2017
Q2 		$1K Buy
+20
New +$330 ﹤0.01% 5558

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Simplex Trading's CRSP Position: Q1 2026 in Review

Simplex Trading opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 1,407 shares worth $66.9K. The stake represents ﹤0.01% of the portfolio and ranks #5538 among its holdings. This is a return to the name: Simplex Trading previously reported a position in CRSP as recently as Q4 2024.

Simplex Trading first reported a position in CRSP in Q3 2017 and has held it in 20 quarters since. The position peaked at $3.27M in Q4 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Simplex Trading held 1,407 shares of CRISPR Therapeutics worth $66.9K as of Q1 2026.
  • CRISPR Therapeutics was a new Simplex Trading position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #5538 holding.
  • Simplex Trading first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 20 quarters since.
  • Simplex Trading's CRISPR Therapeutics position peaked at $3.27M in Q4 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.